


New rules for anticancer vaccines

September 22 2014



This simulation shows structural differences between mutant (yellow) and normal (orange) immune targets called neoepitopes. Researchers reveal how evaluating these distinctions can help pinpoint neoepitopes that elicit anticancer immune responses. Credit: Duan *et al.*, 2014

Scientists have found a way to find the proverbial needle in the cancer antigen haystack, according to a report published in *The Journal of Experimental Medicine*.

As <u>cancer cells</u> divide, they accumulate random mistakes (mutations).



This process creates new versions of proteins, some of which are recognized as foreign invaders by <u>immune cells</u> called T cells, prompting the cells to attack and eliminate the cancer cells. With our current ability to identify all of the mutations in a patient's cancer and to understand which <u>protein sequences</u> can be recognized by T cells, scientists can now predict which mutations will result in new T cell targets (called "neoepitopes"). Some of these neoepitopes can then be used as vaccines to elicit a protective T cell response that destroys the cancer.

But here's the catch. These <u>prediction tools</u> generate hundreds of possible neoepitopes, of which only a handful can actually elicit T cells capable of attacking the tumor. And so far, there has been no reliable common denominator to help pinpoint this useful handful.

Previous attempts to predict cancer neoepitopes have relied on how strongly the mutated protein is recognized by the immune system. But scientists at the University of Connecticut now show that the strength of this interaction is a poor predictor. A better (albeit still imperfect) measure turns out to be how different the mutation looks to the T cell when compared to its normal counterpart—the more distinct, the better. These results have the potential to completely change current approaches to generating anticancer vaccines.

More information: Duan, F., et al. 2014. J. Exp. Med. <u>DOI:</u> 10.1084/jem.20141308

Provided by Rockefeller University

Citation: New rules for anticancer vaccines (2014, September 22) retrieved 27 April 2024 from https://medicalxpress.com/news/2014-09-anticancer-vaccines.html



This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.